Abstract
Ovarian cancer is a highly deadly malignancy in which recurrence is considered incurable. Resistance to platinum-based chemotherapy bodes a particularly abysmal prognosis, underscoring the need for novel therapeutic agents and strategies. The use of mithramycin, an antineoplastic antibiotic, has been previously limited by its narrow therapeutic window. Recent advances in semisynthetic methods have led to mithramycin analogs with improved pharmacological profiles. Mithramycin inhibits the activity of the transcription factor Sp1, which is closely linked with ovarian tumorigenesis and platinum-resistance. This article summarizes recent clinical developments related to mithramycin and postulates a role for the use of mithramycin, or its analog, in the treatment of platinum-resistant ovarian cancer.
Document Type
Review
Publication Date
1-12-2021
Digital Object Identifier (DOI)
https://doi.org/10.3390/biomedicines9010070
Funding Information
This research was funded by a NIH Training Grant, T32CA160003, the 2020 Inter-Departmental Collaboration (IDC) Award from the University of Kentucky College of Pharmacy, and by the University of Kentucky Markey Cancer Center (P30 CA177558).
Repository Citation
Schweer, David; McCorkle, J. Robert; Rohr, Jurgen; Tsodikov, Oleg V.; Ueland, Frederick R.; and Kolesar, Jill M., "Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer" (2021). Obstetrics and Gynecology Faculty Publications. 30.
https://uknowledge.uky.edu/obgyn_facpub/30
Included in
Obstetrics and Gynecology Commons, Oncology Commons, Pharmacy and Pharmaceutical Sciences Commons
Notes/Citation Information
Published in Biomedicines, v. 9, issue 1, 70.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).